BIOMAT Database Logo BIOMAT Database Logo

Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. 1990

C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
INSERM U 25, CNRS UA 122, Hôpital Necker, Paris, France.

In vivo injection of the hamster anti-murine CD3 monoclonal antibody 145 2C11 into BALB/c mice induces a massive systemic release of several cytokines. Very high circulating levels of tumor necrosis factor are detected both by enzyme-linked immunosorbent assay and L-929 bioassay 90 min following a single injection of 10 micrograms/mouse 145 2C11. Peak circulating levels of exclusively T cell-derived products such as interferon-gamma, interleukin 2 and interleukin 3 are also detected 90 min to 8 h post-injection. Importantly, this cytokine release is transient since none of these cytokines are still present 12 to 24 h post-injection. In parallel to cytokine release, 145 2C11-treated mice (10 micrograms/mouse) exhibit somnolence, hypomotility (quantified by actimetry), hypothermia, diarrhea and piloerection. At this dosage, the physical reaction is not lethal and reverses in all mice by 48 h post-injection. Severe but again reversible anatomopathological changes are also observed: massive cellular depletion, necrosis and edema of lymphoid organs, leakage syndrome and inflammatory cell infiltrates of the lung, cell vacuolization, necrosis and vascular congestion of the liver. All these data are similar to the clinical and immunological manifestations of the OKT3-induced reaction in patients and, thus, provide an invaluable experimental tool to study its mechanisms and explore its prevention.

UI MeSH Term Description Entries
D007035 Hypothermia Lower than normal body temperature, especially in warm-blooded animals. Hypothermia, Accidental,Accidental Hypothermia,Accidental Hypothermias,Hypothermias,Hypothermias, Accidental
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008208 Lymphatic System A system of organs and tissues that process and transport immune cells and LYMPH. Lymphatic Systems
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
In vivo T lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody.
August 1990, Transplantation proceedings,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome.
October 1991, Transplantation,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
October 1995, Journal of hematotherapy,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation.
October 1988, Cellular immunology,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
February 1989, Journal of immunology (Baltimore, Md. : 1950),
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
[T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release].
January 1991, Comptes rendus des seances de la Societe de biologie et de ses filiales,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
T cell response to anti-CD3 antibody in Down's syndrome.
November 1987, Archives of disease in childhood,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies.
September 1999, Transplantation,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
In vivo T cell activation properties of anti-T cell monoclonal antibodies.
January 1993, Experimental nephrology,
C Ferran, and K Sheehan, and M Dy, and R Schreiber, and S Merite, and P Landais, and L H Noel, and G Grau, and J Bluestone, and J F Bach
Regulation by anti-CD2 monoclonal antibody of the activation of a human T cell clone induced by anti-CD3 or anti-T cell receptor antibodies.
November 1987, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!